icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Sofosbuvir/Velpatasvir for 12 Weeks in HCV-Infected Patients Previously
Treated With Placebo: Results of the Deferred Treatment Study

 
 
  Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
 
Tarik Asselah,1 Stephen Shafran,2 Stefan Bourgeois,3 Ching-Lung Lai,4 Matthew Cramp,5 Philippe Mathurin,6 Bernard Willems,7 Mindie H. Nguyen,8 Mitchell N. Davis,9 K.C. Huang,10 Evguenia Svarovskaia,10 Anu Osinusi,10 John McNally,10 Diana M. Brainard,10 John G. McHutchison,10 Obaid S. Shaikh,11 Tram T. Tran12
1Universite Paris Diderot, Institut National de la Sante et de la Recherche Medicale U773, Paris, France; 2University of Alberta, Edmonton, Canada, 3Ziekenhuis Netwerk Antwerpen STER Site Stuivenberg, Antwerpen, Belgium; 4The University of Hong Kong, Pokfulam, China; 5Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK; 6H˘pital Claude Huriez, Lille, France; 7Universite de Montreal, Quebec, Canada; 8Stanford University Medical Center, Stanford, California, USA; 9South Florida Center of Gastroenterology, Wellington, Florida, USA; 10Gilead Sciences, Inc., Foster City, California; 11VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA; 12Cedars-Sinai Medical Center, Los Angeles, California

EASL1

EASL2

EASL3

EASL4

EASL5